Drug intelligence / Profile preview

IRX-010

Development stage: Unknown
Lead developer: ImmunoRx Pharma
Administration: Intravenous

Overview

IRX-010 is an investigational drug that was initially developed by ImmunoRx Pharma. It was under development for the treatment of inflammatory diseases and administered intravenously. The drug reached Phase 1 clinical trials, which were designed to evaluate its safety, tolerability, and pharmacokinetics in healthy participants. However, the global highest R&D status for IRX-010 is now listed as discontinued[1][2][3]. Detailed information about its mechanism of action or molecular modality has not been publicly disclosed.

Beyond the preview

Go deeper on IRX-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IRX-010.

Explore the full profile